PDL BioPharma Company Profile (NASDAQ:PDLI)

About PDL BioPharma

PDL BioPharma logoPDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others. It receives royalties on sales of over ten humanized antibody products, which include Avastin, Herceptin, Xolair, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio all of which are approved for use.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: PDLI
  • CUSIP: 69329Y10
Key Metrics:
  • Previous Close: $3.30
  • 50 Day Moving Average: $3.01
  • 200 Day Moving Average: $3.24
  • 52-Week Range: $2.58 - $5.35
  • Trailing P/E Ratio: 2.34
  • Foreward P/E Ratio: 22.00
  • P/E Growth: 0.46
  • Market Cap: $544.63M
  • Outstanding Shares: 165,540,000
  • Beta: 0.78
Profitability:
  • Net Margins: 53.90%
  • Return on Equity: 38.94%
  • Return on Assets: 26.07%
Debt:
  • Debt-to-Equity Ratio: 0.32%
  • Current Ratio: 14.19%
  • Quick Ratio: 14.19%
Additional Links:
Companies Related to PDL BioPharma:

Analyst Ratings

Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $3.75 (13.64% upside)
Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)
Show:
DateFirmActionRatingPrice TargetDetails
8/7/2016Cowen and CompanyReiterated RatingHold$3.50View Rating Details
2/23/2016Royal Bank Of CanadaLower Price TargetSector Perform$5.00 -> $4.00View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for PDL BioPharma (NASDAQ:PDLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/4/2016Q216$0.08$0.09$33.46 million$21.00 millionViewN/AView Earnings Details
5/4/2016Q116$0.50$0.52$142.05 million$103.10 millionViewN/AView Earnings Details
2/22/2016Q415$0.54$0.61$149.20 million$178.10 millionViewListenView Earnings Details
11/4/2015Q315$0.61$0.42$164.80 million$124.60 millionViewN/AView Earnings Details
8/5/2015Q215$0.52$0.47$137.75 million$138.10 millionViewN/AView Earnings Details
5/6/2015Q115$0.52$0.50$140.80 million$149.71 millionViewN/AView Earnings Details
2/23/2015Q414$0.57$0.32$158.15 million$117.10 millionViewListenView Earnings Details
11/10/2014Q314$0.56$0.61$165.10 million$164.60 millionViewN/AView Earnings Details
8/18/2014Q214$0.46$0.52$134.07 million$162.80 millionViewListenView Earnings Details
5/12/2014Q114$0.45$0.44$130.93 million$139.70 millionViewN/AView Earnings Details
3/3/2014Q413$0.43$0.39$115.22 million$110.10 millionViewN/AView Earnings Details
11/6/2013Q313$0.37$0.36$97.09 million$97.30 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.54$0.62$138.20 million$143.60 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.35$0.36$91.69 million$91.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012$0.31$0.34$86.08 million$86.10 millionViewN/AView Earnings Details
11/5/2012Q312$0.33$0.32$85.03 million$85.20 millionViewN/AView Earnings Details
8/2/2012$0.44$0.52ViewN/AView Earnings Details
5/3/2012$0.27$0.29ViewN/AView Earnings Details
2/23/2012$0.28$0.24ViewN/AView Earnings Details
11/9/2011$0.27$0.28ViewN/AView Earnings Details
7/27/2011$0.39$0.39ViewN/AView Earnings Details
4/27/2011$0.24$0.25ViewN/AView Earnings Details
2/28/2011$0.21$0.20ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for PDL BioPharma (NASDAQ:PDLI)
Current Year EPS Consensus Estimate: $0.65 EPS
Next Year EPS Consensus Estimate: $0.15 EPS

Dividends

Current Dividend Information for PDL BioPharma (NASDAQ:PDLI)
Annual Dividend:$0.20
Dividend Yield:6.06%
Payout Ratio:14.29% (Based on Trailing 12 Months of Earnings)
30.77% (Based on Current Year Consensus EPS Estimate)
133.33% (Based on Next Year Consensus EPS Estimate)
Dividend History for PDL BioPharma (NASDAQ:PDLI)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2016quarterly$0.056.25%6/2/20166/6/20166/13/2016
2/1/2016quarterly$0.057.27%3/2/20163/4/20163/11/2016
2/2/2015quarterly$0.158.22%6/1/20166/5/20166/12/2016
1/30/2015quarterly$0.158.23%6/3/20156/5/20156/12/2015
1/30/2015quarterly$0.158.23%3/3/20153/5/20153/12/2015
1/30/2015quarterly$0.158.23%12/2/201512/4/201512/11/2015
1/30/2015quarterly$0.158.23%9/2/20159/4/20159/11/2015
1/31/2014quarterly$0.156.59%9/3/20149/5/20149/12/2014
1/31/2014quarterly$0.156.59%3/3/20143/5/20143/12/2014
1/31/2014quarterly$0.156.59%12/3/201412/5/201412/12/2014
1/31/2014quarterly$0.156.59%6/3/20146/5/20146/12/2014
1/31/2013quarterly$0.158.72%12/3/201312/5/201312/12/2013
1/31/2013quarterly$0.158.72%6/3/20136/5/20136/12/2013
1/31/2013quarterly$0.158.72%9/3/20139/5/20139/12/2013
1/30/2013quarterly$0.158.72%3/1/20133/5/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for PDL BioPharma (NASDAQ:PDLI)
Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 75.22%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Peter S GarciaVPBuy10,000$3.00$30,000.00View SEC Filing  
12/15/2015Peter S. GarciaCFOBuy5,000$3.64$18,200.00View SEC Filing  
12/14/2015Peter S. GarciaCFOBuy10,000$3.42$34,200.00View SEC Filing  
12/7/2015Steffen PietzkeCAOBuy20,590$3.64$74,947.60View SEC Filing  
8/14/2015Peter S GarciaCFOBuy20,000$5.83$116,600.00View SEC Filing  
11/26/2014Harold E SelickDirectorBuy6,000$8.08$48,480.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for PDL BioPharma (NASDAQ:PDLI)
DateHeadline
realistinvestor.com logoPDL BioPharma, Inc. (NASDAQ:PDLI) Accounts Payable At $1.073 - RealistInvestor.com (NASDAQ:PDLI)
www.realistinvestor.com - September 26 at 6:47 PM
News IconActive biotech company shares in the news: PDL BioPharma, Inc. (NASDAQ:PDLI), Anavex Life Sciences Corp ... - The Voice Registrar (NASDAQ:PDLI)
voiceregistrar.com - September 26 at 6:47 PM
News IconHot Biotech Stocks To Watch Right Now: PDL BioPharma, Inc. (PDLI), CTI BioPharma Corp. (CTIC) - The Independent Republic (NASDAQ:PDLI)
theindependentrepublic.com - September 23 at 11:29 AM
capitalcube.com logoPDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : September 20, 2016 (NASDAQ:PDLI)
www.capitalcube.com - September 21 at 10:47 AM
finance.yahoo.com logoWill PDL BioPharma (PDLI) Continue to Surge Higher? (NASDAQ:PDLI)
finance.yahoo.com - September 20 at 11:58 AM
capitalcube.com logoPDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : September 19, 2016 (NASDAQ:PDLI)
www.capitalcube.com - September 19 at 11:13 AM
finance.yahoo.com logoMedical Companies Offer Good Value Opportunities (NASDAQ:PDLI)
finance.yahoo.com - September 16 at 6:31 PM
News IconBiotech news that matter for investors: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), PDL BioPharma, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:PDLI)
voiceregistrar.com - September 16 at 10:12 AM
News IconAnalysts Valuations For Two Stocks: PDL BioPharma (NASDAQ ... - The Voice Registrar (NASDAQ:PDLI)
voiceregistrar.com - September 15 at 6:45 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Mylan, ANI Pharmaceuticals, Cambrex, PDL BioPharma and Innoviva (NASDAQ:PDLI)
finance.yahoo.com - September 14 at 10:59 AM
capitalcube.com logoETF’s with exposure to PDL BioPharma, Inc. : September 8, 2016 (NASDAQ:PDLI)
www.capitalcube.com - September 8 at 6:27 PM
capitalcube.com logoPDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : September 7, 2016 (NASDAQ:PDLI)
www.capitalcube.com - September 7 at 10:15 AM
News IconAnalysts Valuations For Two Stocks: Rowan Companies PLC (NYSE:RDC), PDL BioPharma Inc (NASDAQ:PDLI) - The Voice Registrar (NASDAQ:PDLI)
voiceregistrar.com - September 5 at 5:56 PM
News IconStock Struggling for the Quarter: PDL BioPharma, Inc. (NASDAQ:PDLI) - Post News (NASDAQ:PDLI)
www.kentuckypostnews.com - September 4 at 6:00 PM
stocksdaily.net logoPDL BioPharma, Inc. (NASDAQ:PDLI) Held $220.352 In Cash And Short-Term Investments - Stocks Daily (NASDAQ:PDLI)
www.stocksdaily.net - September 3 at 5:57 PM
News IconTrading the Biotech News: Cerus (NASDAQ:CERS), PDL BioPharma (NASDAQ:PDLI) - The Voice Registrar (NASDAQ:PDLI)
voiceregistrar.com - September 1 at 9:52 AM
istreetwire.com logoStocks in Focus: PDL BioPharma, Inc. (PDLI), Celldex Therapeutics, Inc. (CLDX), Aetna Inc. (AET) - iStreetWire (NASDAQ:PDLI)
istreetwire.com - August 31 at 11:48 AM
News IconGrowth Analysis of PDL BioPharma, Inc. (NASDAQ:PDLI) - Newburg Press (NASDAQ:PDLI)
newburghpress.com - August 31 at 11:48 AM
News IconBiotech Stocks To Put On Your Watch List: PDL BioPharma (NASDAQ:PDLI), Clovis Oncology (NASDAQ:CLVS) - The Voice Registrar (NASDAQ:PDLI)
voiceregistrar.com - August 31 at 11:48 AM
biz.yahoo.com logoPDL BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:PDLI)
biz.yahoo.com - August 29 at 6:32 PM
prnewswire.com logoPDL BioPharma Announces the Successful Conclusion of its Debt Financing Agreement with Paradigm Spine (NASDAQ:PDLI)
www.prnewswire.com - August 29 at 11:14 AM
News IconColumn | There's more than one way to find a great stock (NASDAQ:PDLI)
pilotonline.com - August 28 at 10:44 AM
News IconPDL BioPharma, Inc.'s (PDLI): Trader's Radar - Hot Stocks Point - Hot Stocks Point (NASDAQ:PDLI)
www.hotstockspoint.com - August 27 at 6:02 PM
News IconAnalysts Valuations For Two Stocks: PDL BioPharma Inc (NASDAQ:PDLI), Spirit AeroSystems Holdings, Inc. (NYSE:SPR) - The Voice Registrar (NASDAQ:PDLI)
voiceregistrar.com - August 25 at 6:48 PM
News IconDorfman: Cash flow can provide direction for investing in stock market (NASDAQ:PDLI)
triblive.com - August 23 at 11:11 AM
News IconOn Investments: One method for picking stocks – free cash flow (NASDAQ:PDLI)
www.omaha.com - August 23 at 11:11 AM
News IconPDL BioPharma, Inc.'s (PDLI): Stock under Review - Hot Stocks Point (NASDAQ:PDLI)
www.hotstockspoint.com - August 22 at 6:42 PM
capitalcube.com logoETF’s with exposure to PDL BioPharma, Inc. : August 22, 2016 (NASDAQ:PDLI)
www.capitalcube.com - August 22 at 6:42 PM
News IconSmall Cap Insight on Shares of PDL BioPharma, Inc. (NASDAQ:PDLI) - Duncan Research (NASDAQ:PDLI)
www.duncanindependent.com - August 20 at 6:24 PM
News IconNews review of 2 biotech stocks: PDL BioPharma, Inc. (NASDAQ:PDLI), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - The Voice Registrar (NASDAQ:PDLI)
voiceregistrar.com - August 19 at 6:42 PM
investornewswire.com logoWill PDL BioPharma, Inc. (NASDAQ:PDLI) Hit $4 Price Target? - Investor Newswire (NASDAQ:PDLI)
www.investornewswire.com - August 15 at 7:07 PM
News IconTrading the Biotech News: PDL BioPharma, Inc. (NASDAQ:PDLI), Neuralstem, Inc. (NASDAQ:CUR) - The Voice Registrar (NASDAQ:PDLI)
voiceregistrar.com - August 15 at 7:07 PM
finance.yahoo.com logoPDL BIOPHARMA, INC. Financials (NASDAQ:PDLI)
finance.yahoo.com - August 12 at 6:55 PM
News IconBiotech Stocks Worth a Closer Look: PDL BioPharma, Inc. (NASDAQ:PDLI), Amgen Inc. (NASDAQ:AMGN) - The Voice Registrar (NASDAQ:PDLI)
voiceregistrar.com - August 11 at 7:16 PM
News IconInsider Trading and Share Price Activity: PDL BioPharma Inc (NASDAQ:PDLI) - Post Registrar (NASDAQ:PDLI)
postregistrar.com - August 11 at 7:16 PM
investing.com logoPDL BioPharma - Less Dividend Equals More Deals (NASDAQ:PDLI)
www.investing.com - August 11 at 10:01 AM
capitalcube.com logoPDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:PDLI)
www.capitalcube.com - August 10 at 7:13 PM
News IconHigh Volume Healthcare Stocks: PDL BioPharma, Inc. (NASDAQ:PDLI), Johnson & Johnson (NYSE:JNJ) - TWN (NASDAQ:PDLI)
thewellesleysnews.com - August 9 at 7:01 PM
streetupdates.com logoAnalysts Rating updates about two Stocks: Abbott Laboratories (NYSE:ABT) , PDL BioPharma, Inc. (NASDAQ:PDLI) - Street Updates (NASDAQ:PDLI)
www.streetupdates.com - August 9 at 7:01 PM
fortune.com logoPDL BioPharma, Inc. (NASDAQ:PDLI) Insider Activities Are in the Air - Review Fortune (NASDAQ:PDLI)
reviewfortune.com - August 9 at 7:01 PM
News IconHealthcare Stocks Directions: PDL BioPharma, Inc. (NASDAQ:PDLI), Opko Health, Inc. (NASDAQ:OPK) - TWN (NASDAQ:PDLI)
thewellesleysnews.com - August 9 at 7:01 PM
capitalcube.com logoETF’s with exposure to PDL BioPharma, Inc. : August 9, 2016 (NASDAQ:PDLI)
www.capitalcube.com - August 9 at 7:01 PM
capitalcube.com logoPDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : August 8, 2016 (NASDAQ:PDLI)
www.capitalcube.com - August 8 at 11:29 AM
thestreet.com logoPDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss (NASDAQ:PDLI)
www.thestreet.com - August 5 at 6:59 PM
fool.com logoPDL BioPharma's Stock Crumbles on Dismal Second-Quarter Results (NASDAQ:PDLI)
www.fool.com - August 5 at 3:19 PM
finance.yahoo.com logoPDL BioPharma Announces Second Quarter 2016 Financial Results (NASDAQ:PDLI)
finance.yahoo.com - August 5 at 9:49 AM
finance.yahoo.com logoEdited Transcript of PDLI earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:PDLI)
finance.yahoo.com - August 5 at 9:49 AM
streetinsider.com logoPDL BioPharma (PDLI) Eliminates Qtr Dividend (NASDAQ:PDLI)
www.streetinsider.com - August 4 at 7:14 PM
twst.com logoPDL BioPharma Inc.: PDL BioPharma Announces Elimination of Quarterly Cash Dividend (NASDAQ:PDLI)
www.twst.com - August 4 at 7:14 PM
finance.yahoo.com logoPDL BioPharma Announces Elimination of Quarterly Cash Dividend (NASDAQ:PDLI)
finance.yahoo.com - August 4 at 7:14 PM

Social

PDL BioPharma (NASDAQ:PDLI) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff